NASDAQ:XNCR - Nasdaq - US98401F1057 - Common Stock - Currency: USD
Overall XNCR gets a fundamental rating of 2 out of 10. We evaluated XNCR against 551 industry peers in the Biotechnology industry. XNCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XNCR is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -23.54% | ||
ROE | -33.29% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.16 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.89 | ||
Quick Ratio | 5.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
7.95
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 4.34 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.88 | ||
P/tB | 0.9 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -23.54% | ||
ROE | -33.29% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.16 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 84.11% | ||
Cap/Sales | 7.59% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.89 | ||
Quick Ratio | 5.89 | ||
Altman-Z | 0.24 |